Breaking News Instant updates and real-time market news.

NVS

Novartis

$85.79

-1.16 (-1.33%)

10:25
10/01/19
10/01
10:25
10/01/19
10:25

Novartis to hold a conference call

Management discusses results from the MONALEESA-3 Trial which showed Kisqali (Ribociclib) achieved statistically significant improvement in overall survival, as presented at the ESMO 2019 Annual Meeting, on a conference call to be held on October 1 at 11:30 am. Webcast Link

  • 01

    Oct

NVS Novartis
$85.79

-1.16 (-1.33%)

08/12/19
LEHM
08/12/19
NO CHANGE
Target $31
LEHM
Overweight
Coherus should be bought on weakness from Enbrel ruling, says Barclays
Barclays analyst Balaji Prasad recommends buying shares of Coherus Biosciences (CHRS) on any weakness from Amgen's (AMGN) favorable Enbrel patent ruling against Novartis (NVS). Coherus is developing its own Enbrel generic, says the analyst, whose model already factors a launch in Q2 of 2029, following the expiration of the last U.S. Enbrel patent. As such, Prasad is making no change to his estimates following Friday's decision. He remains positive on Coherus and would use any share weakness as an opportunity to add a "fundamentally sound company." Prasad reiterates an Overweight rating on the shares with a $31 price target.
08/13/19
OPCO
08/13/19
NO CHANGE
Target $230
OPCO
Outperform
Amgen price target raised to $230 from $210 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Amgen (AMGN) to $230 from $210 after the U.S. District Court determined that Sandoz has not met the burden to prove all seven asserted claims invalid and upheld several Enbrel patents. The analyst suspects Sandoz will appeal but views the outcome as highly favorable for Amgen and models flat Enbrel sales until 2021 before declining. Sandoz is a division of Novartis (NVS). Olson reiterates an Outperform rating on Amgen's shares.
09/05/19
09/05/19
UPGRADE
Target $107

Outperform
Incyte upgraded to Outperform from Market Perform at JMP Securities
As previously reported, JMP Securities analyst Reni Benjamin assumed coverage of Incyte (INCY) with an upgraded rating of Outperform and a $107 price target. The analyst cites the "solid fundamentals" of the company's multi-billion dollar Jakafi franchise, including its recent approval in steroid refractory acute graft-versus-host disease, which he believes remains under-appreciated by investors. Benjamin is also positive on Incyte's "marquee" partners that include Novartis (NVS) and Eli Lilly (LLY), along with its $1.7B cash position, diverse pipeline, and strong fundamentals.
09/13/19
DBAB
09/13/19
NO CHANGE
DBAB
Hold
Novartis' ofatumumab to be 'strong' competitor to Roche drug, says Deutsche Bank
Deutsche Bank analyst Richard Parkes tells investors in a research note after attending the ECTRIMS conference in Stockholm that data from Novartis' (NVS) ASCLEPIOS trials suggests ofatumumab will be a "strong" competitor for Roche's (RHHBY) Ocrevus in relapsing/remitting multiple sclerosis. Parkes says he expects physicians to view the drugs as having broadly comparable and highly compelling efficacy, with ofatumumab's at-home dosing an attractive option for some patients, suggesting meaningful upside potential to his current 2024E ofatumumab sales of $1.1B and possible risks to his forecasts for Roche's Ocrevus. According to physician feedback, Parkes says the drugs are likely to share a rapidly growing market. Parkes maintains a Hold rating and 90 CHF price target on Novartis shares.

TODAY'S FREE FLY STORIES

M

Macy's

$16.88

0.02 (0.12%)

05:36
11/19/19
11/19
05:36
11/19/19
05:36
Periodicals
Macy's website breached by hackers in October, The Next Web reports »

Macy's website was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

ABBV

AbbVie

$88.71

0.07 (0.08%)

05:35
11/19/19
11/19
05:35
11/19/19
05:35
Recommendations
AbbVie analyst commentary  »

AbbVie price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

JCDXF

JCDecaux

$0.00

(0.00%)

05:30
11/19/19
11/19
05:30
11/19/19
05:30
Initiation
JCDecaux initiated  »

JCDecaux initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$184.53

0.94 (0.51%)

, ABBV

AbbVie

$88.71

0.07 (0.08%)

05:29
11/19/19
11/19
05:29
11/19/19
05:29
Downgrade
Allergan, AbbVie rating change  »

UBS downgrades Allergan…

AGN

Allergan

$184.53

0.94 (0.51%)

ABBV

AbbVie

$88.71

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ROK

Rockwell Automation

$197.64

-2.58 (-1.29%)

05:25
11/19/19
11/19
05:25
11/19/19
05:25
Downgrade
Rockwell Automation rating change  »

Rockwell Automation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

AGN

Allergan

$184.53

0.94 (0.51%)

05:24
11/19/19
11/19
05:24
11/19/19
05:24
Downgrade
Allergan rating change  »

Allergan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEGXF

Segro

$0.00

(0.00%)

05:22
11/19/19
11/19
05:22
11/19/19
05:22
Downgrade
Segro rating change  »

Segro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JKS

JinkoSolar

$14.88

-0.01 (-0.07%)

05:22
11/19/19
11/19
05:22
11/19/19
05:22
Earnings
JinkoSolar reports Q3 EPS 86c, consensus 83c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 10

    Dec

TRQ

Turquoise Hill

$0.45

(0.00%)

05:20
11/19/19
11/19
05:20
11/19/19
05:20
Hot Stocks
Turquoise Hill notes Administrative Court proceedings in Mongolia »

Turquoise Hill Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRARY

Credit Agricole

$0.00

(0.00%)

05:18
11/19/19
11/19
05:18
11/19/19
05:18
Upgrade
Credit Agricole rating change  »

Credit Agricole upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$369.50

-2.05 (-0.55%)

05:16
11/19/19
11/19
05:16
11/19/19
05:16
Hot Stocks
Boeing: Air Astana intends to buy 30 737 MAX airplanes »

Air Astana intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$22.63

-1.36 (-5.67%)

05:15
11/19/19
11/19
05:15
11/19/19
05:15
Recommendations
Jefferies still expects Amarin shares to rise toward $30 »

Following the data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

BB

BlackBerry

$5.28

-0.195 (-3.56%)

05:15
11/19/19
11/19
05:15
11/19/19
05:15
Hot Stocks
BlackBerry QNX technology to power Arrival intelligent, autonomous-ready EVs »

BlackBerry and electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 06

    Jan

ATRS

Antares Pharma

$4.28

0.12 (2.88%)

05:10
11/19/19
11/19
05:10
11/19/19
05:10
Hot Stocks
Antares Pharma enters into global development agreement with Idorsia »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XONE

ExOne

$7.00

-0.05 (-0.71%)

, ANSS

Ansys

$238.67

3.63 (1.54%)

05:07
11/19/19
11/19
05:07
11/19/19
05:07
Hot Stocks
ExOne announces collaboration with Ansys »

ExOne (XONE) and ANSYS…

XONE

ExOne

$7.00

-0.05 (-0.71%)

ANSS

Ansys

$238.67

3.63 (1.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 02

    Dec

  • 11

    Dec

EIDX

Eidos Therapeutics

$55.16

8.58 (18.42%)

, BBIO

BridgeBio

$29.06

0.8 (2.83%)

05:07
11/19/19
11/19
05:07
11/19/19
05:07
Recommendations
Eidos Therapeutics price target raised to $75 from $55 at Piper Jaffray »

Piper Jaffray analyst…

EIDX

Eidos Therapeutics

$55.16

8.58 (18.42%)

BBIO

BridgeBio

$29.06

0.8 (2.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

PHAT

Phathom Pharmaceuticals

$24.88

-1.12 (-4.31%)

05:01
11/19/19
11/19
05:01
11/19/19
05:01
Initiation
Phathom Pharmaceuticals initiated  »

Phathom Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEG

Leggett & Platt

$53.54

0.18 (0.34%)

04:59
11/19/19
11/19
04:59
11/19/19
04:59
Downgrade
Leggett & Platt rating change  »

Leggett & Platt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

CSL

Carlisle

$161.08

0.12 (0.07%)

04:55
11/19/19
11/19
04:55
11/19/19
04:55
Conference/Events
Carlisle management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

KRP

Kimbell Royalty Partners

$14.18

0.19 (1.36%)

04:55
11/19/19
11/19
04:55
11/19/19
04:55
Conference/Events
Kimbell Royalty Partners management to meet with TD Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

SU

Suncor

$31.84

-0.64 (-1.97%)

04:55
11/19/19
11/19
04:55
11/19/19
04:55
Conference/Events
Suncor management to meet with TD Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

ASML

ASML

$273.38

-1.35 (-0.49%)

, ERIC

Ericsson

$9.10

-0.04 (-0.44%)

04:55
11/19/19
11/19
04:55
11/19/19
04:55
Conference/Events
JPMorgan to hold a conference »

Global TMT…

ASML

ASML

$273.38

-1.35 (-0.49%)

ERIC

Ericsson

$9.10

-0.04 (-0.44%)

IMAX

Imax

$20.88

-0.19 (-0.90%)

SIMO

Silicon Motion

$42.65

0.03 (0.07%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 02

    Dec

  • 09

    Dec

  • 09

    Dec

  • 11

    Dec

  • 06

    Jan

ACCO

Acco Brands

$9.42

0.035 (0.37%)

04:55
11/19/19
11/19
04:55
11/19/19
04:55
Conference/Events
Acco Brands management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

04:55
11/19/19
11/19
04:55
11/19/19
04:55
Conference/Events
Stephens business services analyst to hold a group luncheon »

Group Luncheon Meeting to…

CSGS

CSG

$57.54

0.54 (0.95%)

04:55
11/19/19
11/19
04:55
11/19/19
04:55
Conference/Events
CSG management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.